With Ayushman Bharat nearing its one-year anniversary, the Indian healthcare industry stands at cross-roads leading to untapped potential and a lucrative poster child for the Indian government’s Make in India narrative. To attract investment in the sector, it is imperative that there is no confusion in terms of prevailing law and absolutely no surprises in the form of sudden or unannounced policies that adversely affect innovation. Sidharrth Shankar, Rupinder Malik, Partners, J Sagar Associates and Aman Bhatia, Associate, J Sagar Associates provide an insight
Please click here to read the full article.
Rupinder specializes in mergers & acquisitions, private equity investments, joint ventures, strategic alliances, cross-border investments, regulatory issues for India entry, restructurings of Indian and international conglomerates, as well as compliance and white-collar crime investigations.